**Supplementary Appendix Table 1.**

Previous reports on the use of RTX in thrombocytopenia related to SLE and/or primary SS.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **Response to treatment, N (%)** | | | |  |
|  | **Author,Y** | **patients** | **Complete, >100\*109/l** | **Partial,30-100\*109/l** | **None,**  **<30\*109/l** | **Total N response** | **DIE OR AE** |
| **SLE** | Kenitz,2002 1 | 3 | 1 | 2 | 0 | 0 | 0 |
| Tomietto,2004 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Van den Bergh,2005 3 | 1 | 1 | 0 | 0 | 0 | 0 |
| Ahn,2005 4 | 1 | 1 | 0 | 0 | 0 | 0 |
| Paran,2006 5 | 1 | 1 | 0 | 0 | 0 | 0 |
| Anandacoomarasamy,2006 6 | 1 | 1 | 0 | 0 | 0 | 0 |
| Niewold,2006 7 | 2 | 2 | 0 | 0 | 0 | 0 |
| Ng,2007 8 | 3 | 3 | 0 | 0 | 0 | 0 |
| Lima,2007 9 | 1 | 1 | 0 | 0 | 0 | 0 |
| Fukushima,2008 10 | 1 | 1 | 0 | 0 | 0 | 0 |
| Kittaka,2008 11 | 1 | 1 | 0 | 0 | 0 | 0 |
| Hundae,2008 12 | 1 | 1 | 0 | 0 | 0 | 0 |
| Nadri,2009 13 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reis,2009 14 | 2 | 2 | 0 | 0 | 0 | 0 |
| Mardjuardi,2009 15 | 1 | 1 | 0 | 0 | 0 | 0 |
| Letchumanan,2009 16 | 3 | 1 | 0 | 0 | 0 | 2 |
| Lateef,2010 17 | 3 | 2 | 1 | 0 | 0 | 0 |
| Zheng,2009 18 | 4 | 3 | 0 | 0 | 0 | 1 |
| Lee,2010 19 | 1 | 1 | 0 | 0 | 0 | 0 |
| Terrier,2010 20 | 13 | 10 | 2 | 1 | 0 | 0 |
| Niaz,2010 21 | 1 | 1 | 0 | 0 | 0 | 0 |
| GarcıÅ-Carrasco,2010 22 | 8 | 7 | 0 | 0 | 0 | 1 |
| Chen,2011 23 | 10 | 6 | 2 | 2 | 0 | 0 |
| Gupta,2011 24 | 1 | 1 | 0 | 0 | 0 | 0 |
| Pinto,2011 25 | 1 | 1 | 0 | 0 | 0 | 0 |
| B Jovancevic,2013 26 | 16 | 9 | 4 | 3 | 0 | 0 |
| **SS** | Raphae` le Seror,2007 27 | 1 | 0 | 0 | 1 | 0 | 0 |
| Zhou L,2012 28 | 4 | 4 | 0 | 0 | 0 | 0 |
| Toumeh A, 2014 29 | 1 | 1 | 0 | 0 | 0 | 0 |
| total |  | 88 | 66 | 11 | 7 | 77 | 4 |

**Supplementary Appendix Table 1.**

Previous reports on the use of RTX in thrombocytopenia related to SLE and/or primary SS. CR: complete response; PR: partial response; NR: no response; AE: adverse effects.

**REFERENCES**

1. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. *Immunobiology*. 2002;206:519–527.

2. Tomietto P, Gremese E, Tolusso B, et al. B cell depletion may lead to normalization of antiplatelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. *Thromb Haemost*. 2004;92:150–1153.

3. van den Bergh B, Selleslag D, Boelaert JR, et al. Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature. *Acta Clin Belg*. 2005;60:102–105.

4. Ahn ER, Lander G, Bidot CJ, et al. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. *Am J Hematol*. 2005;78:127–129.

5. Paran D, Trej’o L, Caspi D. Clinical images: B cell depletion in the appendix following rituximab treatment. *Arthritis Rheum*. 2006;54:2151.

6. Anandacoomarasamy A, Gibson J, McGill N. ‘Cure’ of life-threatening antiphospholipid syndrome with rituximab. *Intern Med J*. 2006;36:474–475.

7. Niewold TB, Alpert D, Scanzello CR, et al. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. *J Rheumatol*. 2006;33:1194–1196.

8. Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. *Ann* *Rheum* *Dis*. 2007;66:1259–1262.

9. Limal N, Cacoub P, SèneD, et al. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. *Lupus*. 2008;17:69–71.

10. Fukushima T, Dong L, Sakai T, et al. Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. *Lupus*. 2008;17:210–214.

11. Kittaka K, Dobashi H, Baba N, et al. A case of Evans syndrome combined with systemic lupus erythematosus successfully treated with rituximab. *Scand J Rheumatol*. 2008;37:390–393.

12. Hundae A, Peskoe S, Grimsley E, Patel S. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. *South Med J*. 2008;101:943–944.

13. Nadri QJ. Rituximab to treat active SLE in a hemodialysis patient. *Saudi J Kidney Dis Transpl*. 2009;20:1085–1086.

14. Reis EA, Athanazio DA, Lima I, et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. *Rheumatol Int*. 2009;29:469–475.

15. Mardjuadi A, Soedirman M, Utoyo B, et al. Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia. *Clin Rheumatol*. 2009;28(Suppl 1):S27–S30.

16. Letchumanan P, Ng HJ, Lee LH, et al. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. *Rheumatology (Oxford).* 2009;48:399–403.

17. Lateef A, Lahiri M, Teng GG, et al. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. *Lupus*. 2010;19:765–770.

18. Zheng WJ, Zhang X, Wang Q, et al. Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe? *Ann Rheum Dis*. 2009;68:1077–1078.

19. Lee SY, Hsu PY, Juan KC, et al. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus. *Int Immunopharmacol*. 2010;10:632–634.

20. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. *Arthritis Rheum*. 2010;62:2458–2466.

21. Niaz FA, Aleem A. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. *Saudi J Kidney Dis Transpl*. 2010;21:109–112.

22. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. *Lupus*. 2010;19:213–219.

23. Chen H, Zheng W, Su J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study. *Rheumatology (Oxford)*. 2011;50:1640–1644.

24. Gupta RK, Ezeonyeji AN, Thomas AS, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. *Lupus*. 2011;20:1547–1550.

25. Pinto LF, Velásquez CJ, Prieto C, et al. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. *Lupus*. 2011;20:1219–1226.

26. Jovancevic B, Lindholm C, Pulleritis R. Anti B cell-therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. *Lupus*. 2013;22:664–674.

27. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. *Ann Rheum Dis*. 2007;66:

351–357.

28. Zhou L, Xin XF,Wu HX. The efficacy and safety of low-dose rituximab in treatment of primary Sjogren’s syndrome with thrombocytopenia. *Zhonghua Nei Ke Za Zhi.* 2012;51:37–41.

29. Toumeh A, Josh N, Narwal R, et al. Refractory thrombotic thrombocytopenic purpura associated with primary Sjogren syndrome treated with rituximab: a case report. *Am J Ther*. 2014;21:e56–e60.